Tolerance to treatment in elderly patients with colon cancer
e20710 Background: About 60% of all colorectal cancers occur after the age of 50. This tumor is the second most common cause of cancer and the death by neoplasm. Beside, aging may affect several aspects of pharmacology due to a progressive reserve deteriorations and the comorbidities presence which may influence the tolerance to treatment. Methods: 90 colorectal cancer pts, aged 65–78 years, who underwent surgery and Ch/Rt were included . Pts were divided in two groups: I: ≤ 70 and II > 70 years. Pts selection was conducted using General Geriatric Assessment . All pts had adequate cardiac, hepatic, renal and bone marrow functions. Comorbidities studied were: hypertension, diabetes, COPD, cardiac disease,and gastrointestinal disease.Toxicities were studied following the WHO criteria and correlated according to age, Activity of Daily Living (ADL),Instrumental Activity of Daily Living (IADL), PS, WL, comorbidities, and the use of more than 3 drugs in addition to Ch/ Rxt. QoL was studied through the evaluation of ADL, IADL, and PS evolution. Statistical Methods: Pearson´s Chi-Square test, Kaplan Meier´s curves. Results: The most frequent level in the whole sample was Grade I. No relationship was found between toxicities and age. Toxicity level was found to be higher in the pts who used more than 3 other medications p=0,01. Statistically significant association was found between comorbidities and toxicity levels p = 0,04. WL and toxicity level were statistically associated, p = 0,01. There was improvement in Qol through the evaluation of ADL, PS,and IADL evolution p= 0.03. PS and IADL were statistically correlated with survival p = 0.02 Conclusions: Older Colon cancer pts in good general condition and with controlled comorbidities may receive Ch/ Rxt. The reason why the majority of pts had low toxicities may be attributed to the fact that all of them were properly selected. No significant financial relationships to disclose.